Literature DB >> 30452881

Transcription of the NKG2D ligand MICA is suppressed by the IRE1/XBP1 pathway of the unfolded protein response through the regulation of E2F1.

Akram Obiedat1, Einat Seidel2, Mohamed Mahameed1, Orit Berhani2, Pinchas Tsukerman2, Konstantinos Voutetakis3,4, Aristotelis Chatziioannou3,5, Mari McMahon6,7,8, Tony Avril6,7, Eric Chevet6,7, Ofer Mandelboim2, Boaz Tirosh1.   

Abstract

The unfolded protein response (UPR) is an adaptive signaling pathway activated in response to endoplasmic reticulum (ER) stress. The effectors of the UPR are potent transcription activators; however, some genes are suppressed by ER stress at the mRNA level. The mechanisms underlying UPR-mediated gene suppression are less known. Exploration of the effect of UPR on NK cells ligand expression found that the transcription of NK group 2 member D (NKG2D) ligand major histocompatibility complex class I polypeptide-related sequence A/B (MICA/B) is suppressed by the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) pathway of the UPR. Deletion of IRE1 or XBP1 was sufficient to promote mRNA and surface levels of MICA. Accordingly, NKG2D played a greater role in the killing of IRE1/XBP1 knockout target cells. Analysis of effectors downstream to XBP1s identified E2F transcription factor 1 (E2F1) as linking UPR and MICA transcription. The inverse correlation between XBP1 and E2F1 or MICA expression was corroborated in RNA-Seq analysis of 470 primary melanoma tumors. While mechanisms that connect XBP1 to E2F1 are not fully understood, we implicate a few microRNA molecules that are modulated by ER stress and possess dual suppression of E2F1 and MICA. Because of the importance of E2F1 and MICA in cancer progression and recognition, these observations could be exploited for cancer therapy by manipulating the UPR in tumor cells.-Obiedat, A., Seidel, E., Mahameed, M., Berhani, O., Tsukerman, P., Voutetakis, K., Chatziioannou, A., McMahon, M., Avril, T., Chevet, E., Mandelboim, O., Tirosh, B. Transcription of the NKG2D ligand MICA is suppressed by the IRE1/XBP1 pathway of the unfolded protein response through the regulation of E2F1.

Entities:  

Keywords:  ER stress; NK cells; UPR; immunotherapy

Mesh:

Substances:

Year:  2018        PMID: 30452881     DOI: 10.1096/fj.201801350RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

Review 1.  IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies.

Authors:  Wojciech Wiese; Natalia Siwecka; Adam Wawrzynkiewicz; Wioletta Rozpędek-Kamińska; Ewa Kucharska; Ireneusz Majsterek
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

2.  Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control [version 2; peer review: 2 approved].

Authors:  Mathieu Bléry; Manel Mrabet-Kraiem; Ariane Morel; Florence Lhospice; Delphine Bregeon; Cécile Bonnafous; Laurent Gauthier; Benjamin Rossi; Romain Remark; Stéphanie Cornen; Nadia Anceriz; Nicolas Viaud; Sylvia Trichard; Sabrina Carpentier; Alix Joulin-Giet; Gwendoline Grondin; Veronika Liptakova; Younghoon Kim; Laurent Daniel; Aurélie Haffner; Nicolas Macagno; Laurent Pouyet; Ivan Perrot; Carine Paturel; Yannis Morel; Alexander Steinle; François Romagné; Emilie Narni-Mancinelli; Eric Vivier
Journal:  Open Res Eur       Date:  2021-10-27

Review 3.  NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.

Authors:  Alexandra Frazao; Louise Rethacker; Meriem Messaoudene; Marie-Françoise Avril; Antoine Toubert; Nicolas Dulphy; Anne Caignard
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 4.  The Potential Role of Mitochondrial Acetaldehyde Dehydrogenase 2 in Urological Cancers From the Perspective of Ferroptosis and Cellular Senescence.

Authors:  Weizhen Zhu; Dechao Feng; Xu Shi; Qiang Wei; Lu Yang
Journal:  Front Cell Dev Biol       Date:  2022-04-20

5.  IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response.

Authors:  Adriana Martinez-Turtos; Rachel Paul; Manuel Grima-Reyes; Hussein Issaoui; Adrien Krug; Rana Mhaidly; Jozef P Bossowski; Johanna Chiche; Sandrine Marchetti; Els Verhoeyen; Eric Chevet; Jean-Ehrland Ricci
Journal:  Oncoimmunology       Date:  2022-08-27       Impact factor: 7.723

Review 6.  The Role of the Hypoxia-Related Unfolded Protein Response (UPR) in the Tumor Microenvironment.

Authors:  Sylwia Bartoszewska; James F Collawn; Rafal Bartoszewski
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

Review 7.  Endoplasmic reticulum stress signals in the tumour and its microenvironment.

Authors:  Xi Chen; Juan R Cubillos-Ruiz
Journal:  Nat Rev Cancer       Date:  2020-11-19       Impact factor: 60.716

8.  Inositol-Requiring Enzyme 1α-Mediated Synthesis of Monounsaturated Fatty Acids as a Driver of B Cell Differentiation and Lupus-like Autoimmune Disease.

Authors:  Yana Zhang; Ming Gui; Yajun Wang; Nikita Mani; Shuvam Chaudhuri; Beixue Gao; Huabin Li; Yashpal S Kanwar; Sarah A Lewis; Sabrina N Dumas; James M Ntambi; Kezhong Zhang; Deyu Fang
Journal:  Arthritis Rheumatol       Date:  2021-11-02       Impact factor: 10.995

9.  The integrated stress response promotes B7H6 expression.

Authors:  Akram Obiedat; Yoav Charpak-Amikam; Julie Tai-Schmiedel; Einat Seidel; Mohamed Mahameed; Tony Avril; Noam Stern-Ginossar; Lorraine Springuel; Jennifer Bolsée; David E Gilham; Priya Dipta; Miriam Shmuel; Eric Chevet; Ofer Mandelboim; Boaz Tirosh
Journal:  J Mol Med (Berl)       Date:  2019-12-14       Impact factor: 4.599

10.  Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene.

Authors:  Benedetta M Santoliquido; Michela Frenquelli; Claudia Contadini; Stefano Bestetti; Marco Gaviraghi; Elisa Barbieri; Anna De Antoni; Luca Albarello; Angelo Amabile; Alessandro Gardini; Angelo Lombardo; Claudio Doglioni; Paolo Provero; Silvia Soddu; Davide Cittaro; Giovanni Tonon
Journal:  Life Sci Alliance       Date:  2021-06-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.